Key result
Aliskiren/hydrochlorothiazide reduces SBP by ~16 mmHg compared to aliskiren alone.
Why the study?
The efficacy, safety, and tolerability of aliskiren/hydrochlorothiazide single-pill combinations in patients with hypertension inadequately responsive to aliskiren monotherapy were evaluated.
Does a single-pill combination of aliskiren/hydrochlorothiazide improve blood pressure reduction in patients with hypertension and an inadequate response to aliskiren monotherapy?
RCT (n=880)
Double-blind
randomized
Does a single-pill combination of aliskiren/hydrochlorothiazide improve blood pressure reduction in patients with hypertension and an inadequate response to aliskiren monotherapy?
Aliskiren/hydrochlorothiazide single-pill combinations provide clinically significant additional blood pressure reductions and improved control rates compared to aliskiren monotherapy in non-responders.
Answers are grounded in this paper and cite their sources.
Aliskiren/HCT SPC improves BP control in nonresponders; extends RCT evidence for combinations in resistant hypertension.
OBJECTIVES: To evaluate the efficacy, safety and tolerability of a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT) in patients with hypertension and an inadequate BP response to aliskiren monotherapy (mean sitting diastolic BP [msDBP] > 90 and < or = 110 mmHg following 4 weeks of aliskiren 300 mg). METHODS: In this study, 880 patients with hypertension and an inadequate BP response to aliskiren monotherapy were randomized to once-daily, double-blind treatment with a single-pill combination of aliskiren/HCT 300/25 mg or 300/12.5 mg, or aliskiren 300 mg monotherapy. At the week 8 endpoint, least-squares mean changes in mean sitting systolic/diastolic BP (msSBP/DBP) from baseline were analyzed for the intent-to-treat population. RESULTS: Aliskiren/HCT 300/25 mg and 300/12.5 mg provided significantly greater msSBP/DBP reductions from baseline (15.9/11.0 mmHg and 13.5/10.5 mmHg, respectively) than aliskiren 300 mg alone (8.0/7.4 mmHg; both p<0.001). Rates of BP control (<140/90 mmHg) were significantly higher with aliskiren/HCT 300/25 mg (60.2%) and 300/12.5 mg (57.9%) than with aliskiren 300 mg alone (40.9%; both p<0.001). Aliskiren/HCT single-pill combination treatment showed similar tolerability to aliskiren monotherapy. CONCLUSIONS: Aliskiren/HCT single-pill combinations provide clinically significant additional BP reductions and improved BP control rates over aliskiren alone in patients who are non-responsive to aliskiren 300 mg monotherapy.
No takes yet. Share an insight, caveat, or question.
Nickenig et al. (2008) conducted an RCT in hypertension with inadequate BP response to aliskiren monotherapy (n=880). aliskiren/hydrochlorothiazide vs. aliskiren 300 mg monotherapy was evaluated on least-squares mean changes in mean sitting systolic/diastolic BP from baseline (p=<0.001). Aliskiren/hydrochlorothiazide 300/ and 300/ reduced msSBP/DBP by 15.9/11.0 and 13.5/10.5 mmHg vs 8.0/7.4 mmHg with aliskiren alone.
Synapse has enriched 10 related papers. Consider them for comparative context: